CHAPTER 4 REFERENCES

Abbas, D., Chong, E. and Raymond, E.. Outpatient medical abortion is safe and effective through 70days gestation. Contraception, 2015;92(3), pp.197-199. https://bit.ly/3IcQyT0

Aiken ARA, Digol I, Trussel J, Gomperts R. Self Reported Outcomes and Adverse Events After Medical Abortion Through Online Telemedicine. BMJ. 2017 May 16;357:j2011. https://bit.ly/2X4Kl7u

Aiken A, Starling J, Scott, J. Association of Texas Senate Bill 8 with Requests for Self-Managed Medication Abortion. JAMA Network Open. 2022;5(2):e221122. doi:10.1001/jamanetworkopen.2022.1122. https://bit.ly/3MM7FyB

Aiken A, et al., 2021. Effectiveness, safety and acceptability of no‐test medical abortion provided via telemedicine: a national cohort study. BJOG: An International Journal of Ob/Gyn, 128(9), pp.1464-1474. https://bit.ly/35Sm7o4

Akin MD, Weingand KW, Hengehold DA, et al. Continuous low-level topical heat in the treatment of dysmenorrhea. Obstetrics & Gynecology, 2001; 97(3), pp.343-349. https://bit.ly/3KH02aI

Ashok, PW, Penney GC, Flett GMM, et al. An effective Regimen for Early Medical Abortion:  A Report of 200 Consecutive Cases. Hum Reprod 1998;13:2962-2965.  http://goo.gl/XWLvH

Barnhart K, Hansen KR, Stephenson MD, et al. Effect of an Active vs Expectant Management Strategy on Successful Resolution of Pregnancy Among Patients With a Persisting Pregnancy of Unknown Location: The ACT or NOT Randomized Clinical Trial. JAMA. 2021 Aug 3;326(5):390-400.  https://bit.ly/36fsn94

Blum J, Raghavan S, Dabash R, et al. Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam. Int J Gynaecol Obstet. 2012;118:166-71. https://bit.ly/3enUIsU

Boersma AA, Meyboom-de Jong B, Kleiverda G. Mifepristone followed by home administration of buccal misoprostol for medical abortion up to 70 days of amenorrhoea. Eur J Contracept Reprod Health Care. 2011 Apr;16(2):61-6. http://goo.gl/tHwKax

Bracken H, Clark W, Lichtenberg ES, et al. Alternatives to routine ultrasound for eligibility assessment prior to early termination of pregnancy with mifepristone–misoprostol. BJOG. 2011;118(1):17-23. https://bit.ly/3bSvQIj

Bracken H, Dabash R, Tsertsvadze G,  et al. A two-pill sublingual misoprostol outpatient regimen following mifepristone for medical abortion through 70 days’ LMP: a prospective open-label trial. Contraception. 2014 Mar;89(3):181-6. http://goo.gl/ze0c6k

Brandi K, Woodhams E, White K O, et al. An exploration of perceived contraceptive coercion at the time of abortion. Contraception. 2018 Apr;97(4):329-334. https://bit.ly/2X2BXFu

Chai J, Wong CY, Ho PC. A randomized clinical trial comparing the short-term side effects of sublingual and buccal routes of misoprostol administration for medical abortions up to 63 days’ gestation. Contraception. 2013 Apr;87(4):480-5. http://goo.gl/5MDxnW

Chen MJ, Creinin MD. Mifepristone with buccal misoprostol for medical abortion: a systematic review. Obstet Gynecol. 2015 Jul;126(1):12-21. http://bit.ly/2NFIHEf

Creinin MD, Fox MC, Teal S, et al.  A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion.  Obstet Gynecol 2004 May;103(5 Pt 1):851-859.  http://goo.gl/EnwDD

Creinin MD, Hou MY, Dalton L, et al. Mifepristone antagonization with progesterone to prevent medical abortion: a randomized controlled trial. Obstet Gynecol. 2020 Jan; 135(1):158-165. https://bit.ly/2KiG2hr

Colwill AC, Bayer LL, Bednarek P, et al. Opioid Analgesia in Medication Abortion: A Randomized Control Trial. Obstet Gynecol 2019 Dec;134(6):1163-1170. https://bit.ly/2X44Tg5

Danco: FDA Package Label; Current Mifeprex materials March 2016. https://bit.ly/37HYECD; FDA Mifepristone Q&A 2021. https://bit.ly/3KJaxu9

Dragoman MV, Grossman D, Nguyen MH, et al. Two prophylactic pain management regimens for medical abortion ≤63 days’ gestation with mifepristone and misoprostol: A multicenter, randomized, placebo-controlled trial. Contraception. 2021;103(3):163-170. https://bit.ly/3PkfQUd

Dzuba IG, Castillo PW, Bousiéguez M, et al. A repeat dose of misoprostol 800mcg following mifepristone for outpatient medical abortion at 64-70 and 71-77 days of gestation: A retrospective chart review. 2020 May. Contraception. 2020;S0010-7824(20)30160-8. https://bit.ly/2Z0htNr

Dzuba IG, Chong E, Hannum C, et al. A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64-70 days and 71-77 days of gestation. Contraception. 2020 May;101(5):302-308. https://bit.ly/2UPnvy8

Fiala C, Safar P, Bygdeman M, et al. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol. 2003; 109: 190-195. https://bit.ly/2xQJ2il

Fiastro A, Wells E, Coeytaux F, Godfrey E. ACCESS, DELIVERED: A Toolkit for Providers Offering Medication Abortion. University of Washington ResearchWorks. Published 2021. Accessed [January 2022] https://bit.ly/3MAFjqs

Fjerstad M, Trussell J, Lichtenberg ES, et al. Severity of infection following the introduction of new infection control measures for medical abortion. Contraception. 2011 Apr;83(4):330-5.  http://goo.gl/PXlnh

Friedlander EKB, Soon R, Salcedo J, Davis J, Tschann M, Kaneshiro B. Prophylactic pregabalin to decrease pain during medication abortion. Obstetrics & Gynecology. 2018;132(3):612-618. https://bit.ly/3NfK0WH

Gatter M, Cleland K, Nucatola DL. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days. Contraception 2015 April 91(4): 269-73. http://goo.gl/lAK88G

Goldman AR, Porsch L, Hintermeister A, Dragoman M. Transcutaneous electrical nerve stimulation to reduce pain with medication abortion. Obstetrics & Gynecology. 2020;137(1):100-107. https://bit.ly/3MeLBvP

Grossman D, Grindlay K. Alternatives to Ultrasound for Follow-up After Medication Abortion: A Systemic Review. Contraception. 2011; 83(6):504–510. https://bit.ly/2V3KC8f

Grossman D, et al. Effectiveness and acceptability of medical abortion provided through telemedicine. Obstet Gynecol. 2011 Aug;118(2 Pt 1):296-303. http://goo.gl/sPSaIJ

Grossman D, Grindlay K, Buchacker T, et al. Continuing pregnancy after mifepristone “reversal” of first-trimester medical abortion: a systematic review. Contraception. 2015 Sep;92(3):206-11. https://bit.ly/2ROWsTc

Hamoda H, Ashok PW, Flett GM, et al. Medical Abortion at 64 to 91 days of gestation: a Review of 483 Consecutive Cases. Am J Obstet Gynecol. 2003 May;188(5):1315-9. http://bit.ly/2TCgku9

Hamoda H, Ashok PW, Flett GM, Templeton Al. A Randomised Controlled Trial of Mifepristone in Combination with Misoprostol Administered Sublingually or Vaginally for Medical Abortion up to 13 Weeks gestation. BJOG. 2005 Aug;112(8):1102-8. https://bit.ly/2Vmqhwr

Hollenbach SJ, Cochran M, Harrington A.”Provoked” feto-maternal hemorrhage may represent insensible cell exchange in pregnancies from 6 to 22 weeks gestational age. Contraception. 2019 Aug;100(2):142-146. https://bit.ly/2JERDqK

Horvath S, Tsao P, Huang ZY, et al. The concentration of fetal red blood cells in first-trimester pregnant women undergoing uterine aspiration is below the calculated threshold for Rh sensitization. Contraception 2020. https://bit.ly/2wjmDty

Hsia JK, Lohr PA, Taylor J, et al. Medical abortion with mifepristone and vaginal misoprostol between 64 and 70 days’ gestation. Contraception. 2019;100(3):178-81. https://bit.ly/39rUSwp

Ipas Clinical Updates in Reproductive Health:

Misoprostol only: Recommended Regimen Before 13 Weeks Gestation. Published 2021. https://bit.ly/35UQfPJ

Recommendations for Abortion At or After 13 Weeks Gestation: Medication Abortion.. Published 2021. https://bit.ly/38JhRsu

Jones RK, Nash E, Cross L, et al. Medication Abortion Now Accounts for More Than Half of All US Abortions. Guttmacher Institute 2022. https://bit.ly/3q8vjLM

Jones RK, Witwer E, Jerman J. Abortion Incidence and Service Availability in the United States, 2017. Guttmacher Institute, 2019. http://bit.ly/3akfPLk

Kapp N, Eckersberger E, Lavelanet A, Rodriguez MI. Medication Abortion in the Late First Trimester: A Systematic Review. Contraception. 2019 Feb;99(2):77-86. https://bit.ly/2UMeu9e

KFF. State Restrictions on Telehealth Abortion, 2022. https://bit.ly/3J8TmSl

Kulier R, Kapp N, Gulmezoglu A M, et al. Medical methods for first trimester abortion. Cochrane Database Syst Rev. 2011 Nov 9;2011(11):CD002855. https://bit.ly/2X2GR5a

Larsson A, Rönnberg AM. Expanding a woman’s options to include home use of misoprostol for medical abortion up until 76 days. Acta Obstet Gynecol Scand. 2019; 98: 747-752. https://bit.ly/39o1Nqd

Lokeland M, Iverson OE, Dahle GS, et al. Medical abortion at 63 to 90 days of gestation. Obstetrics & Gynecology. 2010 May;115(2), 962-968. https://bit.ly/2UIBtBW

Mark A, Foster AM, Grossman D, et al. Forgoing Rh testing and anti-D immunoglobulin for women presenting for early abortion: NAF’s Clinical Policies Committee. Contraception. 2019 May;99(5):265-266. http://bit.ly/2RvmdqB

Meites E, Zane S, Gould C; C. sordellii Investigators. Fatal Clostridium sordellii infections after medical abortions. N Engl J Med. 2010 Sep 30;363(14):1382-3.  https://bit.ly/3hNkt8a

Middleton T, Schaff E, Fielding SL, et al. Randomized trial of mifepristone and misoprostol for abortion through 56 days of LMP. Contraception 2005;72:328-332.  http://goo.gl/hGXes

Moreno-Ruiz NL, Borgatta L, Yanow S, Kapp N, Wiebe ER, Winikoff B. Alternatives to Mifepristone for Early Medical Abortion. Int J Gynaecol Obstet. 2007 Mar;96(3):212-8. http://bit.ly/2TEBwzW

Moseson H, Jayaweera R, Egwuatu I, et al. Effectiveness of self-managed medication abortion with accompaniment support in Argentina and Nigeria (SAFE): a prospective, observational cohort study and non-inferiority analysis with historical controls. Lancet Glob Health. 2022 Jan;10(1):e105-e113. https://bit.ly/3tiijF8

Murtagh C, Wells E, Raymond EG, et al. Exploring the feasibility of obtaining mifepristone and misoprostol from the internet. Contraception. 2017; 92: 297-301. https://bit.ly/2xuTf3I

NAF Clinical Policy Guidelines 2022. https://bit.ly/3PEzJFI

Oppegaard KS, Qvigstad E, Fiala C, et al. Clinical follow-up compared with self-assessment of outcome after medical abortion: a multicentre, non-inferiority, randomised, controlled trial. Lancet. 2015 Feb 21;385(9969):698-704. http://goo.gl/fTxe2V

Ralph LJ, Ehrenreich K, Barar R, et al. Accuracy of self-assessment of gestational duration among people seeking abortion. American Journal of Obstetrics and Gynecology. 2021. https://bit.ly/3DEOFO9

Raymond EG, Mark A, Grossman D, et al. No-Test Medication Abortion: A Sample Protocol for Increasing Access During a Pandemic and Beyond. Contraception. 2020 Apr; epub ahead of print. https://bit.ly/3bluPZA

Raymond EG, Tan YL, Comendant R, et al. Simplified medical abortion screening: a demonstration project. Contraception. 2018 Apr;97(4):292-296. https://bit.ly/36CAdGg

Raymond EG, Weaver MA, Louie KS, et al. Effects of DMPA Injection Timing on Medical Abortion Efficacy and Repeat Pregnancy: An RCT. Obstet Gynecol. 2016 Oct;128(4):739-45. http://bit.ly/2G2yeOL

Raymond EG, Weaver MA, Tan YL, et al. Effect of Immediate Compared With Delayed Insertion of Etonogestrel Implants on Medical Abortion Efficacy and Repeat Pregnancy. Obstet Gynecol. 2016 Feb;127(2):306-12. http://goo.gl/ML5XId

Raymond, E. Anger HA, Chong E, et al. “False positive” urine pregnancy test results after successful medication abortion. Contraception, 2021, 103(6), pp.400-403. https://bit.ly/3q3sI5X

Reeves MF, Fox MC, Lohr PA, et al. Endometrial Thickness Following Medical Abortion Is not Predictive of Subsequent Surgical Intervention. Ultrasound Obstet Gynecol. 2009;34(1):104-9. http://goo.gl/nWW3Al

Reeves MF, Kudva A, Creinin MD. Medical abortion outcomes after a second dose of misoprostol for persistent gestational sac. Contraception. 2008 Oct;78(4):332-5. http://goo.gl/NdEyFD

Reeves MF, Monmaney JA, Creinin MD. Predictors of uterine evacuation following early medical abortion with mifepristone and misoprostol. Contraception. 2016 Feb;93(2):119-25. http://goo.gl/Fvh0Fg

Sääv I, et al. Early versus delayed insertion of intrauterine contraception after medical abortion – a randomized controlled trial. PLoS One. 2012;7(11):e48948. http://goo.gl/5o3Uk8

Sanhueza Smith P, Peña M, Dzuba IG, et al. Safety, efficacy and acceptability of outpatient mifepristone-misoprostol medical abortion through 70 days since last menstrual period in public sector facilities in Mexico City. Reprod Health Matters. 2015 Feb;22(44 Suppl 1):75-82. http://goo.gl/QXEZnA

Schaff EA, Eisinger SH, Stadalius LS, et al. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion.  Contraception 1999 Jan;59(1):1-6.  http://goo.gl/jzk3F

Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. Contraception 2002 Oct;66(4):247-250. http://goo.gl/LMcUJ

Schaff EA, Fielding SL, Westhoff C, Ellertson C, Eisinger SH, Stadalius LS, Fuller L. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial. JAMA. 2000 Oct 18;284(15):1948-53. Erratum in: JAMA 2000 Nov 22-29;284(20):2597. https://bit.ly/3LfnADG

Schmidt-Hansen M, et al. Follow-up Strategies to Confirm the Success of Medical Abortion of Pregnancies Up to 10 Weeks’ Gestation: A systematic Review with Meta-Analysis. Am J Obstet Gynecol. 2019 Nov 9. http://bit.ly/2TFjoFS

Schmidt-Hansen M, Lord J, Hasler E, Cameron S. Simultaneous compared to interval administration of mifepristone and misoprostol for medical abortion up to 10+0 weeks’ gestation: a systematic review with meta-analyses. BMJ Sex Reprod Health. 2020 Oct;46(4):270-278. https://bit.ly/3yES8fa

Schonberg D, Wang LF, Bennett AH, et al. The accuracy of using last menstrual period to determine gestational age for first trimester medication abortion: a systematic review. Contraception. 2014;90:480-7. https://bit.ly/2VCLj96

Seeber BE, Barnhart KT. Suspected ectopic pregnancy. Obstet Gynecol. 2006 Feb;107(2 Pt 1):399-413. Review. Erratum in: Obstet Gynecol. 2006 Apr;107(4):955. http://goo.gl/Li5tzr

Snyder H, et al. Managing pain for patients using Medication-Assisted Treatment for Opioid Use Disorder. National Abortion Federation (NAF), December 2018. https://bit.ly/3MUrHa3

Sheldon WR, Durocher J, Dzuba IG, et al. Early Abortion with Buccal vs Sublingual Misoprostol Alone: a Multicenter Randomized Trial. Contraception. 2019 May;99(5):272-277. http://bit.ly/368bvvt

Society of Family Planning Clinical Guideline. Medical management of first-trimester abortion. Contraception 89(3) 2014, pp. 148–161. http://goo.gl/BJiETT

Stillman M, Owolabi O, Fatusi AO, et al. Women’s self-reported experiences using misoprostol obtained from drug sellers: a prospective cohort study in Lagos State, Nigeria. BMJ Open. 2020;10:e034670. https://bit.ly/2TK4AVX

Tang OS, Chan CC, Ng EH, et al. A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Hum Reprod. 2003 Nov;18(11):2315-8. http://goo.gl/RMgL5k

Tang OS, et al. The effect of contraceptive pills on the measured blood loss in medical termination of pregnancy by mifepristone and misoprostol Hum Reprod. 2002;17:99–102. https://bit.ly/2RcGMsw

Upadhyay UD, Raymond EG, Koenig LR, Coplon L, Gold M, Kaneshiro B, Boraas CM, Winikoff B. Outcomes and Safety of History-Based Screening for Medication Abortion: A Retrospective Multicenter Cohort Study. JAMA Intern Med. 2022 May 1;182(5):482-491. https://bit.ly/3a3d3yi

Von Hertzen H, Huong NTM, Piaggio G,et al. Misoprostol dose and route after mifepristone for early medication abortion: a randomized controlled noninferiority trial. BJOG. 2010 Aug; 117:1186-1196. https://bit.ly/2ZFBOJV

Winikoff B, Dzuba IG, Chong E, et al. Extending outpatient medical abortion services through 70 days of gestational age. Obstet Gynecol. 2012 Nov;120(5):1070-6. http://goo.gl/cLx0eM

World Health Organization. Abortion Care Guideline. Geneva, 2022. https://bit.ly/35UOKB5